Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Biohaven Ltd. BHVN NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
48/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.29
+105.3%

Biohaven Ltd. (BHVN) is a Biotechnology company in the Healthcare sector, currently trading at $10.37. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is BHVN = $21 (+105.3% upside).

Valuation: BHVN trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.1.

Net income is $739M (loss), growing at -22.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $279M against $52M equity (Debt-to-Equity (D/E) ratio 5.36, leveraged). Current ratio is 3.18 (strong liquidity). Debt-to-assets is 61.8%. Total assets: $451M.

Analyst outlook: 18 / 25 analysts rate BHVN as buy (72%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 40/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).

$21.29
▲ 105.3% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Biohaven Ltd., the average price target is $21.29, with a high forecast of $42.00, and a low forecast of $10.00.
Highest Price Target
$42.00
Average Price Target
$21.29
Lowest Price Target
$10.00

BHVN SharesGrow Score Overview

58/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BHVN

✓
VALUE Pass
100/100
BHVN trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25). Forward PEG 0.1 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $21, implying +102.5% from the current price $10. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
BHVN: +0%/yr revenue is, -22.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet BHVN: Debt-to-Equity (D/E) ratio 5.36 (leveraged), Current ratio is 3.18 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
BHVN: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 18 / 25 analysts rate BHVN as buy (72%). Analyst consensus target is $21 (+102.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.48-24.06
Volume1.92M
Avg Volume (30D)2.33M
Market Cap$1.1B
Beta (1Y)3.62
Share Statistics
EPS (TTM)-6.86
Shares Outstanding$107.62M
IPO Date2022-09-23
Employees256
CEOVladimir Coric
Financial Highlights & Ratios
Gross Profit$-4.14M
EBITDA$-727.46M
Net Income$-738.82M
Operating Income$-745.38M
Total Cash$319.14M
Total Debt$278.86M
Net Debt$48.9M
Total Assets$451.45M
Price / Earnings (P/E)-1.5
Analyst Forecast
1Y Price Target$22.00
Target High$42.00
Target Low$10.00
Upside+112.2%
Rating ConsensusBuy
Analysts Covering25
Buy 72% Hold 28% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINVGG1110E1079

Price Chart

Track all markets on TradingView
BHVN
Biohaven Ltd. ↗  ·  NYSE
Healthcare • Biotechnology
7.48 52WK RANGE 24.06

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$152.54
+3.76%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.00
-0.96%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
-0.01%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 VERA
VERA
Vera Therapeutics, Inc.
$43.45
-2.05%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message